190A
Chordia Therapeutics Inc.
Ｃｈｏｒｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(-)
Aug 2024
-
Aug 2025
-
Operating profit(thousand JPY)
Aug 2024
-1,801,396
Aug 2025
-1,789,781
Operating profit margin(-)
Aug 2024
-
Aug 2025
-
Profit before tax(thousand JPY)
Aug 2024
-1,824,707
Aug 2025
-1,783,447
Profit(thousand JPY)
Aug 2024
-1,827,127
Aug 2025
-1,785,867
Total assets(thousand JPY)
Aug 2024
4,632,370
Aug 2025
2,681,349
Cash and cash equivalents(thousand JPY)
Aug 2024
4,329,624
Aug 2025
2,548,955
Cash flows from operating activities(thousand JPY)
Aug 2024
-1,937,248
Aug 2025
-1,836,921
Cash flows from investing activities(thousand JPY)
Aug 2024
-10,959
Aug 2025
-5,327
Cash flows from financing activities(thousand JPY)
Aug 2024
1,478,797
Aug 2025
61,580
Return on equity(-)
Aug 2024
-
Aug 2025
-
Equity ratio(%)
Aug 2024
89.8
Aug 2025
90.8
Earnings per share(JPY per share)
Aug 2024
-31.11
Aug 2025
-26.03
Net assets per share(JPY per share)
Aug 2024
61.44
Aug 2025
35.29
Dividend per share(-)
Aug 2024
-
Aug 2025
-
Payout ratio(-)
Aug 2024
-
Aug 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.